Company intelligence / Profile preview

Teraklin

Ownership: Private
Development stage: Other

Overview

Teraklin AG developed the MARS therapy system, a medical device for extracorporeal liver support, used for treating patients with severe liver disease. MARS supports detoxification in cases of liver failure by removing albumin-bound toxins. There are numerous peer-reviewed publications and documented clinical use validating its clinical benefit in acute or chronic liver failure, drug intoxication, and other hepatic conditions. No evidence of new product development since the 2010s.

Therapeutic areas: Gastroenterology
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Teraklin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Teraklin.

Explore the full profile